panitumumab
takeda,amgen
['3503', 'improve', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
 #improvestudy is on stage at #asco22 abs.3503 intermittent vs continuous folfiri/panitumumab as 1line for pts with ras/braf wt mcrc #stopandgo for #antiegfr: yes or no? can't wait for the #oralabstractsession #mcrc 6 jun 2022 | 16:45 19:45 cest
MD, PhD. GI Medical Oncologist @istitutotumori. @myESMO #YOC & #SoMe committee member. European. Beauty seeker. Tweets are my own.